P423 NF-kB as a prognostic marker of response to biologic therapy in children with IBD
ECCO'20 Vienna
2020
P424 Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada
ECCO'20 Vienna
2020
P425 SPOSIB SB2: a Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar SB2
ECCO'20 Vienna
2020
P427 A hybrid approach of handling missing data in inflammatory bowel disease (IBD) trials: results from VISIBLE 1 and VARSITY
ECCO'20 Vienna
2020
P428 Oral mesalamine use in Crohn’s disease after implementation of the American College of Gastroenterology guidelines: a TARGET-IBD cohort study
ECCO'20 Vienna
2020
P429 Clinical utility of thiopurine metabolite monitoring in inflammatory bowel disease and its impact on healthcare utilisation in Singapore
ECCO'20 Vienna
2020
P430 Feasibility and reliability of gastrointestinal ultrasound in pregnant inflammatory bowel disease patients
ECCO'20 Vienna
2020
P432 Effects and safety of a colon-long absorbing budesonide product in patients with mild to moderate ulcerative colitis
ECCO'20 Vienna
2020
P433 A real-world observational study assessing treatment persistence in ulcerative colitis patients receiving anti-TNF treatment (golimumab or adalimumab)
ECCO'20 Vienna
2020
P434 Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from Eneida Registry
ECCO'20 Vienna
2020
P435 Real-world clinical outcomes after elective discontinuation of first-use biologics in IBD patients
ECCO'20 Vienna
2020
P436 Evaluation of targeted vitamin D supplementation regimen in postoperative patients with Crohn’s disease
ECCO'20 Vienna
2020
P438 Real-life effectiveness and safety of ABP501, an adalimumab biosimilar, in inflammatory bowel disease: a multicentre Italian study
ECCO'20 Vienna
2020
P439 Patient’ recruitment for a Phase 3 inflammatory bowel disease (IBD) programme is significantly increased when accessing the CT-SCOUT™ platform
ECCO'20 Vienna
2020
P440 Polimedication in patients with inflammatory bowel disease: prevalence and outcomes in a retrospective unicentric series
ECCO'20 Vienna
2020